MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
BioNano Genomics Financial Ratios 2011-2025 | BNGO
Annual Financial Ratios BioNano Genomics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.0 | -0.0 | -0.3 | -8.5 | -35.7 | -1.3 | -2.2 | - | - | - | - | - | - | - |
P/S |
0.1 | 0.0 | 1.3 | 34.2 | 172.8 | 3.7 | 3.4 | - | - | - | - | - | - | - |
EPS |
-88.1 | -408.6 | -4.6 | -0.3 | -0.4 | -2.0 | -2.6 | -8.7 | - | - | - | - | - | - |
EV (Enterprise Value) |
35.7 M | 101 M | 90 M | 630 M | 1.46 B | 46.6 M | 39 M | 60.4 M | 42 M | - | - | - | - | - |
EBITDA per Share |
-70.8 | -354 | -4.22 | -0.27 | -0.279 | -0.722 | -1.9 | - | - | - | - | - | - | - |
EV/EBITDA |
-7.7 | -39.6 | -1.6 | -1.7 | - | - | - | - | - | - | - | |||
PEG |
-0.0 | -0.0 | - | -0.65 | -0.02 | -0.03 | - | - | - | - | - | - | - | |
P/B |
0.1 | 0.0 | 0.1 | 1.8 | 41.9 | 10.3 | 4.0 | - | - | - | - | - | - | - |
P/CF |
-0.1 | -0.0 | -0.3 | -8.5 | -38.3 | -1.3 | -2.0 | - | - | - | - | - | - | - |
ROE % |
-316.66 | -241.78 | -53.17 | -21.49 | -117.17 | -825.05 | -182.46 | - | - | - | - | - | - | - |
ROA % |
-146.10 | -108.44 | -43.12 | -19.21 | -68.00 | -98.70 | -74.57 | - | - | - | - | - | - | - |
ROCE % |
-293.94 | -223.85 | -52.81 | -22.87 | -74.85 | -673.68 | -100.67 | - | - | - | - | - | - | - |
Current Ratio |
1.9 | 1.8 | 5.3 | 9.4 | 5.2 | 1.1 | 5.1 | - | - | - | - | - | - | - |
DSO |
83.4 | 82.6 | 78.5 | 78.2 | 119.1 | 228.2 | 137.3 | - | - | - | - | - | - | - |
DIO |
245.4 | 394.3 | 351.9 | 203.1 | 211.2 | 185.7 | 44.8 | - | - | - | - | - | - | - |
DPO |
104.1 | 157.5 | 194.6 | 177.2 | 186.6 | 145.6 | 56.6 | - | - | - | - | - | - | - |
Operating Cycle |
328.9 | 476.9 | 430.4 | 281.4 | 330.3 | 413.9 | 182.1 | - | - | - | - | - | - | - |
Cash Conversion Cycle |
224.7 | 319.3 | 235.8 | 104.2 | 143.7 | 268.4 | 125.4 | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios BioNano Genomics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.59 | -1.99 | -1.15 | - | -30.92 | -14.41 | -35.75 | - | -3.22 | -1.24 | -1.23 | - | -1.1 | -1.13 | -0.11 | - | -0.07 | -0.07 | -0.04 | - | -0.08 | -0.09 | -0.3 | - | -0.59 | -0.71 | -0.77 | - | -0.63 | -0.98 | -1.16 | - | -1.74 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | -2.24 | - | - | - | -32 | - | - | - | -1.15 | - | -0.87 | -1.12 | -0.1 | - | -0.07 | -0.06 | -0.04 | - | -0.07 | -0.08 | -0.27 | - | -0.5 | -0.61 | -0.58 | - | -0.72 | -1.08 | -1.19 | - | -1.64 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-129.17 | -202.65 | -207.73 | -148.71 | -243.30 | -247.35 | -245.27 | -128.75 | -140.04 | -56.74 | -49.91 | -32.21 | -38.29 | -33.07 | -27.21 | -14.25 | -45.01 | -69.70 | -87.28 | -83.74 | -302.39 | -448.66 | -602.68 | -791.32 | -635.91 | -507.47 | -363.10 | -182.46 | -131.00 | -35.89 | -3.22 | 34.73 | 46.52 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-74.38 | -114.27 | -117.79 | -83.08 | -144.96 | -156.19 | -157.99 | -88.93 | -98.75 | -46.70 | -40.96 | -27.03 | -32.80 | -20.14 | -25.41 | -13.62 | -31.47 | -43.55 | -51.65 | -48.59 | -74.75 | -78.07 | -85.90 | -94.66 | -94.36 | -93.04 | -85.21 | -74.57 | 9.63 | -200.82 | -187.47 | -171.96 | -230.31 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-141.75 | -214.44 | -218.44 | -148.63 | -243.77 | -249.06 | -246.15 | -129.76 | -141.17 | -57.44 | -50.44 | -32.30 | -38.35 | -33.00 | -26.49 | -13.90 | -43.05 | -66.14 | -82.57 | -78.17 | -235.48 | -363.63 | -531.81 | -517.82 | -576.70 | -478.27 | -328.48 | -141.23 | -131.21 | -62.31 | -22.73 | 10.02 | 10.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
2.7 | 2.5 | 2.6 | 1.9 | 2.3 | 2.6 | 2.1 | 1.8 | 2.9 | 4.8 | 4.8 | 5.3 | 7.7 | - | 9.4 | 9.4 | 19.9 | 32.6 | 17.4 | 2.4 | 2.4 | 2.4 | 2.4 | 1.1 | 1.1 | 1.1 | 1.1 | 1.7 | 1.7 | 1.7 | 1.7 | 0.6 | 0.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
49.7 | 46.4 | 57.3 | - | 86.9 | 85.5 | 91.7 | - | 79.7 | 75.8 | 84.9 | - | 36.8 | 37.7 | 83.7 | - | 57.2 | 57.1 | 68.7 | - | 115.3 | 214.2 | 365.8 | 207.2 | 174.5 | 265.7 | 267.1 | 102.6 | 145.6 | 121.5 | 202.9 | 107.5 | 55.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
213.8 | 304.4 | 320.1 | - | 123.9 | 413.1 | 394.5 | - | 458.2 | 470.8 | 536.7 | - | 211.2 | 142.8 | 270.4 | - | 181.3 | 149.6 | 136.4 | - | 207.2 | 501.8 | 360.3 | 185.9 | 132.3 | 202.1 | 179.5 | 32.6 | 31.8 | 53.8 | 149.8 | 103.3 | 45.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
139.7 | 179.4 | 175.3 | - | 54.8 | 163.4 | 155.2 | - | 189.5 | 198.8 | 241.7 | - | 79.3 | 57.8 | 153.7 | - | 151.4 | 112.4 | 110.3 | - | 183.1 | 443.4 | 300.0 | 145.7 | 103.7 | 158.4 | 161.1 | 41.3 | 40.2 | 68.0 | 198.2 | 140.5 | 62.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
263.5 | 350.8 | 377.4 | - | 210.8 | 498.6 | 486.2 | - | 537.9 | 546.6 | 621.6 | - | 248.0 | 180.5 | 354.1 | - | 238.4 | 206.8 | 205.0 | - | 322.6 | 716.0 | 726.1 | 393.1 | 306.8 | 467.8 | 446.6 | 135.3 | 177.4 | 175.3 | 352.7 | 210.8 | 101.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
123.8 | 171.4 | 202.1 | - | 156.1 | 335.1 | 331.0 | - | 348.4 | 347.8 | 379.9 | - | 168.7 | 122.7 | 200.4 | - | 87.0 | 94.4 | 94.7 | - | 139.4 | 272.6 | 426.1 | 247.4 | 203.1 | 309.5 | 285.5 | 94.0 | 137.2 | 107.3 | 154.6 | 70.3 | 39.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company BioNano Genomics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M |  USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
$ 64.79 | 2.0 % | $ 25 B | USA |
 |
Brainsway Ltd.
BWAY
|
$ 17.23 | 1.5 % | $ 99.4 M | Israel |
 |
Burning Rock Biotech Limited
BNR
|
$ 21.15 | 11.37 % | $ 233 M |  China |
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
$ 101.24 | 0.04 % | $ 18.8 B | USA |
 |
Biomerica
BMRA
|
$ 2.31 | 2.01 % | $ 5.31 M | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
$ 0.36 | -0.39 % | $ 10.6 M | USA |
 |
Guardant Health
GH
|
$ 104.81 | -0.39 % | $ 12.9 B | USA |
 |
Celcuity
CELC
|
$ 98.24 | -0.25 % | $ 3.88 B | USA |
 |
DarioHealth Corp.
DRIO
|
$ 11.75 | -0.47 % | $ 333 M | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 185.09 | 2.99 % | $ 15.3 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 733.11 | 0.57 % | $ 60.5 B | USA |
 |
Danaher Corporation
DHR
|
$ 228.08 | 1.74 % | $ 167 B | USA |
 |
Illumina
ILMN
|
$ 128.88 | 0.12 % | $ 20.5 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 4.25 | -3.41 % | $ 136 K | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 267.33 | -0.14 % | $ 22.4 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 58.6 | -0.81 % | $ 4.06 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 589.45 | 0.25 % | $ 18.2 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 457.09 | -0.75 % | $ 30.9 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 7.06 | -0.03 % | $ 640 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 5.81 | -1.43 % | $ 3.12 M | USA |
 |
NeoGenomics
NEO
|
$ 12.02 | -0.04 % | $ 1.52 B | USA |
 |
Neogen Corporation
NEOG
|
$ 5.91 | -0.25 % | $ 1.28 B | USA |
|
Biodesix
BDSX
|
$ 7.79 | - | $ 1.01 B | USA |
 |
National Research Corporation
NRC
|
$ 16.27 | -3.1 % | $ 399 M | USA |
 |
Natera
NTRA
|
$ 237.72 | 1.48 % | $ 23.4 B | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Castle Biosciences
CSTL
|
$ 39.24 | 0.31 % | $ 1.09 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 184.06 | 0.16 % | $ 20.4 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 28.38 | -0.49 % | $ 858 M | USA |
 |
Organovo Holdings
ONVO
|
- | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
- | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
$ 2.33 | 4.69 % | $ 591 M | USA |
 |
PerkinElmer
PKI
|
- | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
$ 24.56 | 8.81 % | $ 31.9 M | USA |
 |
Personalis
PSNL
|
$ 10.09 | 4.18 % | $ 598 M | USA |
 |
RadNet
RDNT
|
$ 79.11 | -1.13 % | $ 5.78 B | USA |
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M |  Germany |
 |
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | China |